Post by M&G

The UK is home to world-class science and innovation. Helping promising businesses scale is an important part of what we do.     Through our Crossover Strategy, M&G invested £30 million in 4basebio, a UK biotechnology company whose synthetic DNA technology supports the development of genetic medicines, including vaccines, cell and gene therapies, and personalised cancer treatments.  During our recent media reception, we asked Amy Walker, CEO of 4basebio, to tell us more about the growth of the company and to explain how it is challenging established approaches to DNA manufacturing and helping drug developers bring new treatments closer to patients. "Our role is to support ambitious businesses as they scale – providing capital, building strong working relationships with management teams, and sharing our experience as they execute on their growth plans. We take particular pride in helping British companies become global champions in their field, and 4basebio stands out as a prime example of the extraordinary science and innovation coming out of the UK." - Cornel Chiriac, Investment Director for the Crossover Strategy at M&G Investments. This investment is a clear example of our integrated business model in action, and exactly what #PruFunded is all about: actively putting pension saver money to work in opportunities that can deliver long-term value. Capital from our £70 billion PruFund range is invested and actively managed by M&G Investments on behalf of our Life business, giving investors access to a broader range of opportunities through a diversified portfolio spanning both public and private markets. That includes innovative, high-growth businesses such as 4basebio.

Video Content